Wishing you all the joys of the season! 
Middle East & Africa Cell and Gene Therapy Manufacturing Services Market Forecast to 2030
Middle East & Africa Cell and Gene Therapy Manufacturing Services Market Forecast to 2030 – Regional Analysis – by Type [Cell Therapy (Autologous and Allogenic) and Gene Therapy (Viral and Non-Viral Vector)], Indication (Cancer, Orthopedics, and Others), Application (Clinical Manufacturing and Commercial Manufacturing), and End User [Pharmaceutical and Biotechnology Companies and Contract Research Organization (CROs)]
$2,485 – $3,885
- Description
- Toplines
- Reasons for Buying
- Table of Contents
- List of Tables
- LIst of Figures
- List of Companies
- Reviews (0)
Description
Strategic Initiatives by Companies Drive Middle East & Africa Cell and Gene Therapy Manufacturing Services Market
Companies operating in the Middle East & Africa cell and gene therapy manufacturing services market focus on strategic developments such as collaborations, expansions, agreements, partnerships, and new product launches, which help them improve their sales, expand their geographic reach, and enhance their capacities to cater to a larger than existing customer base. A few of the noteworthy developments in the cell and gene therapy manufacturing services market are mentioned below.
• In May 2023, Lonza launched the TheraPEAK T-VIVO Cell Culture Medium with a novel chemically defined formulation devised to optimize and streamline CAR T-cell manufacturing. The TheraPEAK T-VIVO Cell Culture Medium can exhibit a high performance without the need to add human serum or its components, unlike other serum-free media.
• In October 2022, Pfizer Inc. completed the acquisition of Biohaven Pharmaceutical Holding Company Ltd., the manufacturer of NURTEC ODT (rimegepant), an innovative migraine therapy approved for both acute treatment and prevention of episodic migraine in adults.
• In March 2022, Cellevolve Bio partnered with Seattle Children’s Therapeutics to develop and commercialize new multiplex CARs for paediatric cancers. Under the collaboration, the partners will focus on the BrainChild research program, a suite of five multiplex CARs, to treat pediatric central nervous system (CNS) malignancies. In partnership, they would leverage the Seattle Children’s Cure Factory facility to conduct early clinical GMP research on new CARs.
• In March 2022, Twist Bioscience Corporation and Kriya Therapeutics, Inc. entered an antibody discovery agreement for antibodies delivered using adeno-associated viral (AAV) gene therapy in therapeutic oncology applications. Upon collaboration, the companies had plans of combining Twist’s antibody libraries with Kriya’s proprietary vector engineering platform to discover novel antibodies against specific targets of interest to be delivered with Kriya’s gene therapy technology.
Thus, these strategic initiatives create significant growth opportunities in the Middle East & Africa cell and gene therapy manufacturing services market.
Middle East & Africa Cell and Gene Therapy Manufacturing Services Market Overview
The UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa are major countries in the Middle East & Africa. In June 2022, the United Arab Emirates University (UAEU) researchers had successfully used the gene-editing technology CRISPR-Cas9 to understand disease mechanisms which might provide an opportunity to develop novel therapies. The process of rejuvenation, replacement, regenerating, and restoring cells and restoring healthy function is called regenerative medicine. Regenerative Medicine has already become a strong market in the UAE, and it is expected to grow even more. In healthcare clinics and cities, there are several regenerative medicine options available, especially for musculoskeletal ailments, cardiovascular diseases, and cosmetic dermatology. Several trends in UAE’s healthcare sector favour the development of regenerative medicine. The UAE is shifting away from importing drugs and therapeutic products in favour of allocating funds for local drug and therapeutic manufacturing. Government investment in biomedical research and development is also on the rise. This includes advanced biotherapies like cell therapy, immunomodulation therapy, gene therapy, and tissue engineering. Further, in September 2022, Gilead established a fully functional cell therapy business unit and CAR T-Cell therapy operations in Saudi Arabia. Gilead and Kite Middle East launched the “Saudi Arabia’s Vision 2030” in which Kite selected Saudi Arabia as the location of its first Middle East operation. The aim of the vision is to establish fully functional oncology/cell therapy business unit in line with international best-in-class protocols for cancer treatment. Thus, aforementioned factors are boosting the growth of Middle East and Africa cell and gene therapy manufacturing services market.
Middle East & Africa Cell and Gene Therapy Manufacturing Services Market Revenue and Forecast to 2030 (US$ Million)
Middle East & Africa Cell and Gene Therapy Manufacturing Services Market Segmentation
The Middle East & Africa cell and gene therapy manufacturing services market is segmented into type, indication, application, end user, and country.
Based on type, the Middle East & Africa cell and gene therapy manufacturing services market is bifurcated into cell therapy and gene therapy. In 2022, the cell therapy segment registered a larger share in the Middle East & Africa cell and gene therapy manufacturing services market. The cell therapy segment is further segmented into autologous and allogenic. The gene therapy segment is further segmented into viral and non-viral vector.
Based on indication, the Middle East & Africa cell and gene therapy manufacturing services market is segmented into cancer, orthopedics, and others. In 2022, the cancer segment registered the largest share in the Middle East & Africa cell and gene therapy manufacturing services market.
Based on application, the Middle East & Africa cell and gene therapy manufacturing services market is segmented into clinical manufacturing and commercial manufacturing. In 2022, the commercial manufacturing segment registered the largest share in the Middle East & Africa cell and gene therapy manufacturing services market.
Based on end user, the Middle East & Africa cell and gene therapy manufacturing services market is bifurcated into pharmaceutical and biotechnology companies and contract research organization (CROs). In 2022, the pharmaceutical and biotechnology companies segment registered a larger share in the Middle East & Africa cell and gene therapy manufacturing services market.
Based on country, the Middle East & Africa cell and gene therapy manufacturing services market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. In 2022, Saudi Arabia registered the largest share in the Middle East & Africa cell and gene therapy manufacturing services market.
Lonza Group AG, Merck KgaA, Nikon Corp, Takara Bio Inc, Thermo Fisher Scientific Inc, and WuXi AppTec Co LtdÄ are some of the leading companies operating in the Middle East & Africa cell and gene therapy manufacturing services market.
Summary Info
| Industry: | |
|---|---|
| Pricing options: | |
| Geographical coverage: | |
| Year of Publication: |
According to the research team’ research, the Middle East & Africa cell and gene therapy manufacturing services market was valued at US$ 254.68 million in 2022 and is expected to reach US$ 854.98 million by 2030, registering a CAGR of 16.3% from 2022 to 2030. Automation of cell and gene therapy manufacturing services and strategic initiatives by companies are among the critical factors attributed to the Middle East & Africa cell and gene therapy manufacturing services market expansion.
Incorporating automation in cell and gene therapy manufacturing would lead to a reduced risk of contamination, improved consistency, and decreased cost of production. Lonza Cocoon and the CliniMACS Prodigy system from Miltenyi are a few of the devices available in the market to enable automation. These products have been designed to enable the automation of most sequential unit operations for a CAR-T process within a single system. The rising demand for cell and gene therapies has shifted the production of cell and gene therapy products from a small-volume process to a large-volume process worldwide. In addition to the increasing research activities, the evolution of cell and gene therapy from an academic and clinical setting to mass production and commercialization has propelled the demand for automation in commercial manufacturing. In July 2020, Thermo Fisher Scientific Inc. and Lyell Immunopharma partnered to develop and manufacture processes to design effective cell therapies for cancer patients. Under this partnership, the companies aim to improve the capability of T-cells and support the development of an integrated current good manufacturing practice (cGMP) compliant platform (system and software), along with reagents, consumables, and instruments. Further, government agencies are adopting automation in the manufacturing of cell therapies to increase the national production capabilities of the country. Thus, automation is emerging as a new trend in the Middle East & Africa cell and gene therapy manufacturing services market.
On the contrary, high cost of cell and gene therapy manufacturing hurdles the growth of Middle East & Africa cell and gene therapy manufacturing services market.
Based on type, the Middle East & Africa cell and gene therapy manufacturing services market is bifurcated into cell therapy and gene therapy. The cell therapy segment held 68.0% share of Middle East & Africa cell and gene therapy manufacturing services market in 2022, amassing US$ 173.27 million. It is projected to garner US$ 589.02 million by 2030 to expand at 16.5% CAGR during 2022-2030. The cell therapy segment is further segmented into autologous and allogenic. The gene therapy segment is further segmented into viral and non-viral vector.
Based on indication, the Middle East & Africa cell and gene therapy manufacturing services market is segmented into cancer, orthopedics, and others. The cancer segment held 45.6% share of Middle East & Africa cell and gene therapy manufacturing services market in 2022, amassing US$ 116.02 million. It is projected to garner US$ 417.49 million by 2030 to expand at 17.4% CAGR during 2022-2030.
Based on application, the Middle East & Africa cell and gene therapy manufacturing services market is segmented into clinical manufacturing and commercial manufacturing. The commercial manufacturing segment held 62.9% share of the Middle East & Africa cell and gene therapy manufacturing services market in 2022, amassing US$ 160.07 million. It is projected to garner US$ 566.13 million by 2030 to expand at 17.1% CAGR during 2022-2030.
Based on end user, the Middle East & Africa cell and gene therapy manufacturing services market is bifurcated into pharmaceutical and biotechnology companies and contract research organization (CROs). The pharmaceutical and biotechnology companies segment held 79.0% share of Middle East & Africa cell and gene therapy manufacturing services market in 2022, amassing US$ 201.16 million. It is projected to garner US$ 679.87 million by 2030 to expand at 16.4% CAGR during 2022-2030.
Based on country, the Middle East & Africa cell and gene therapy manufacturing services market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Our regional analysis states that Saudi Arabia captured 46.8% share of Middle East & Africa cell and gene therapy manufacturing services market in 2022. It was assessed at US$ 119.17 million in 2022 and is likely to hit US$ 407.36 million by 2030, exhibiting a CAGR of 16.6% during 2022-2030.
Key players operating in the Middle East & Africa cell and gene therapy manufacturing services market are Lonza Group AG, Merck KgaA, Nikon Corp, Takara Bio Inc, Thermo Fisher Scientific Inc, and WuXi AppTec Co Ltd, among others.
o Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Middle East & Africa cell and gene therapy manufacturing services market.
o Highlights key in order to assist companies to realign their business strategies
o The key findings and recommendations highlight crucial progressive industry trends in the Middle East & Africa cell and gene therapy manufacturing services market, thereby allowing players across the value chain to develop effective long-term strategies
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
o Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the cell and gene therapy manufacturing services market, as well as those hindering it
o Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution.
TABLE OF CONTENTS
1. Introduction
1.1 The Research Team Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Middle East & Africa Cell and Gene Therapy Manufacturing Services Market – Key Industry Dynamics
4.1 Key Market Drivers:
4.1.1 Increase in Number of Approval of Cell and Gene Therapies
4.1.2 Increasing Popularity of Outsourcing Cell and Gene Therapy Manufacturing
4.2 Market Restraints
4.2.1 High Cost of Cell and Gene Therapy Manufacturing
4.3 Market Opportunities
4.3.1 Strategic Initiatives by Companies
4.4 Future Trends
4.4.1 Automation of Cell and Gene Therapy Manufacturing Services
4.5 Impact Analysis:
5. Cell and Gene Therapy Manufacturing Services Market – Middle East & Africa Market Analysis
5.1 Middle East & Africa Cell and Gene Therapy Manufacturing Services Market Revenue (US$ Mn), 2022 – 2030
6. Middle East & Africa Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 – by Type
6.1 Overview
6.2 Middle East & Africa Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Type 2022 & 2030 (%)
6.3 Cell Therapy
6.3.1 Overview
6.3.2 Cell Therapy: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
6.3.2.1 Autologous
6.3.2.1.1 Overview
6.3.2.1.2 Autologous: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
6.3.2.2 Allogenic
6.3.2.2.1 Overview
6.3.2.2.2 Allogenic: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
6.4 Gene Therapy
6.4.1 Overview
6.4.2 Gene Therapy: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
6.4.2.1 Viral Vector
6.4.2.1.1 Overview
6.4.2.1.2 Viral Vector: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
6.4.2.2 Non-Viral Vector
6.4.2.2.1 Overview
6.4.2.2.2 Non-Viral Vector: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
7. Middle East & Africa Cell and Gene Therapy Manufacturing Services Market Analysis and Forecasts to 2030 – by Indication
7.1 Overview
7.2 Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by Indication 2022 & 2030 (%)
7.3 Cancer
7.3.1 Overview
7.3.2 Cancer: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Orthopedics
7.4.1 Overview
7.4.2 Orthopedics: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Others
7.5.1 Overview
7.5.2 Others: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
8. Middle East & Africa Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 – by Application
8.1 Overview
8.2 Middle East & Africa Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Application 2022 & 2030 (%)
8.4 Clinical Manufacturing
8.4.1 Overview
8.4.2 Clinical Manufacturing: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Commercial Manufacturing
8.5.1 Overview
8.5.2 Commercial Manufacturing: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
9. Middle East & Africa Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 – by End User
9.1 Overview
9.2 Middle East & Africa Cell and Gene Therapy Manufacturing Services Market Revenue Share, by End User 2022 & 2030 (%)
9.4 Pharmaceutical and Biotechnology Companies
9.4.1 Overview
9.4.2 Pharmaceutical & Biotechnology Companies: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
9.5 Contract Research Organizations (CROs)
9.5.1 Overview
9.5.2 Contract Research Organizations (CROs): Middle East & Africa Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
10. Middle East & Africa Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 – Country Analysis
10.1 Overview
10.1.1 Middle East & Africa: Cell and Gene Therapy Manufacturing Services Market, by Country, 2022 & 2030 (%)
10.1.1.1 South Africa: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.1.1 South Africa: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
10.1.1.1.1.1 South Africa: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
10.1.1.1.1.2 South Africa: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
10.1.1.1.2 South Africa: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
10.1.1.1.3 South Africa: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
10.1.1.1.4 South Africa: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
10.1.1.2 Saudi Arabia: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.1 Saudi Arabia: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
10.1.1.2.1.1 Saudi Arabia: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
10.1.1.2.1.2 Saudi Arabia: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
10.1.1.2.2 Saudi Arabia: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
10.1.1.2.3 Saudi Arabia: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
10.1.1.2.4 Saudi Arabia: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
10.1.1.3 UAE: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.1 UAE: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
10.1.1.3.1.1 UAE: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
10.1.1.3.1.2 UAE: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
10.1.1.3.2 UAE: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
10.1.1.3.3 UAE: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
10.1.1.3.4 UAE: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
10.1.1.4 Rest of Middle East & Africa: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.4.1 Rest of Middle East & Africa: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
10.1.1.4.1.1 Rest of Middle East & Africa: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
10.1.1.4.1.2 Rest of Middle East & Africa: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
10.1.1.4.2 Rest of Middle East & Africa: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
10.1.1.4.3 Rest of Middle East & Africa: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
10.1.1.4.4 Rest of Middle East & Africa: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
11. Middle East & Africa Cell and Gene Therapy Manufacturing Services Market – Industry Landscape
11.1 Overview
11.2 Growth Strategies in Middle East & Africa Cell and Gene Therapy Manufacturing Services Market
11.3 Organic Growth Strategies
11.3.1 Overview
11.4 Inorganic Growth Strategies
11.4.1 Overview
12. Company Profiles
12.1 Thermo Fisher Scientific Inc
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Merck KGaA
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Lonza Group AG
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 WuXi AppTec Co Ltd?
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Nikon Corp
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Takara Bio Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
LIST OF TABLES
Table 1. Middle East & Africa Cell and Gene Therapy Manufacturing Services Market Segmentation
Table 2. South Africa: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
Table 3. South Africa: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
Table 4. South Africa: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
Table 5. South Africa: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
Table 6. South Africa: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
Table 7. South Africa: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
Table 8. Saudi Arabia: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
Table 9. Saudi Arabia: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
Table 10. Saudi Arabia: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
Table 11. Saudi Arabia: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
Table 12. Saudi Arabia: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
Table 13. Saudi Arabia: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
Table 14. UAE: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
Table 15. UAE: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
Table 16. UAE: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
Table 17. UAE: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
Table 18. UAE: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
Table 19. UAE: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
Table 20. Rest of Middle Reat and Africa: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
Table 21. Rest of Middle East & Africa: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
Table 22. Rest of Middle East & Africa: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
Table 23. Rest of Middle East & Africa: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
Table 24. Rest of Middle East & Africa: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
Table 25. Rest of Middle East and Africa: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
Table 26. Recent Organic Growth Strategies in Middle East & Africa Cell and Gene Therapy Manufacturing Services Market
Table 27. Recent Inorganic Growth Strategies in the Middle East & Africa Cell and Gene Therapy Manufacturing Services Market
LIST OF FIGURES
Figure 1. Middle East & Africa Cell and Gene Therapy Manufacturing Services Market Segmentation, By Country
Figure 2. Middle East & Africa Cell and Gene Therapy Manufacturing Services Market – Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Middle East & Africa Cell and Gene Therapy Manufacturing Services Market Revenue (US$ Mn), 2022 – 2030
Figure 5. Middle East & Africa Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Type 2022 & 2030 (%)
Figure 6. Cell Therapy: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 7. Autologous: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Allogenic: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Gene Therapy: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. Viral Vector: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Non-Viral Vector: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. Middle East & Africa Cell and Gene Therapy Manufacturing Services Market, by Indication 2022 & 2030 (%)
Figure 13. Cancer: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. Orthopedics: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 15. Others: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. Middle East & Africa Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Application 2022 & 2030 (%)
Figure 17. Clinical Manufacturing: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. Commercial Manufacturing: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 19. Middle East & Africa Cell and Gene Therapy Manufacturing Services Market Revenue Share, by End User 2022 & 2030 (%)
Figure 20. Pharmaceutical & Biotechnology Companies: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 21. Contract Research Organizations (CROs): Middle East & Africa Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 22. Middle East & Africa: Cell and Gene Therapy Manufacturing Services Market, by Key Region – Revenue (2022) (US$ Million)
Figure 23. Middle East & Africa: Cell and Gene Therapy Manufacturing Services Market, by Country, 2022 & 2030 (%)
Figure 24. South Africa: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 25. Saudi Arabia: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 26. UAE: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 27. Rest of Middle East & Africa: Middle East & Africa Cell and Gene Therapy Manufacturing Services Market – Revenue and Forecast to 2030 (US$ Million)
Figure 28. Growth Strategies in Middle East & Africa Cell and Gene Therapy Manufacturing Services Market
The List of Companies – Middle East & Africa Cell and Gene Therapy Manufacturing Services Market
1. Lonza Group AG
2. Merck KgaA
3. Nikon Corp
4. Takara Bio Inc
5. Thermo Fisher Scientific Inc
6. WuXi AppTec Co Ltd
You must be logged in to post a review.
Reviews
There are no reviews yet.